Literature DB >> 7474141

Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

J Goncalves1, B Shi, X Yang, D Gabuzda.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) encodes a Vif protein which is important for virus replication and infectivity. Vif is a cytoplasmic protein which exists in both membrane-associated and soluble forms. The membrane-associated form is an extrinsic membrane protein which is tightly associated with the cytoplasmic side of membranes. We have analyzed the mechanism of membrane targeting of Vif and its role in HIV-1 replication. Mutagenesis studies demonstrate that C-terminal basic domains are required for membrane association. Vif mutations which disrupt membrane association also inhibit HIV-1 replication, indicating that membrane localization of Vif is likely to be required for its biological activity in vivo. Membrane binding of Vif is almost completely abolished by trypsin treatment of membranes. These results demonstrate that membrane localization of Vif requires C-terminal basic domains and interaction with a membrane-associated protein(s). This interaction may serve to direct Vif to a specific cellular site, since immunofluorescence staining and plasma membrane fractionation studies show that Vif is localized predominantly to an internal cytoplasmic compartment rather than to the plasma membrane. The mechanism of membrane targeting of Vif is different in some respects from that of other extrinsic membrane proteins, such as Ras, Src, and MARCKS, which utilize a basic domain together with a lipid modification for membrane targeting. Membrane targeting of Vif is likely to play an important role in HIV-1 replication and thus may be a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474141      PMCID: PMC189641     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

Review 2.  Fatty acylation of proteins.

Authors:  A M Schultz; L E Henderson; S Oroszlan
Journal:  Annu Rev Cell Biol       Date:  1988

Review 3.  The biology and enzymology of eukaryotic protein acylation.

Authors:  D A Towler; J I Gordon; S P Adams; L Glaser
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

4.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

5.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

Review 6.  Peptides with affinity for membranes.

Authors:  E T Kaiser; F J Kézdy
Journal:  Annu Rev Biophys Biophys Chem       Date:  1987

7.  Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line.

Authors:  H M Rho; B Poiesz; F W Ruscetti; R C Gallo
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

8.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

9.  Role of vif during packing of the core of HIV-1.

Authors:  S Höglund; A Ohagen; K Lawrence; D Gabuzda
Journal:  Virology       Date:  1994-06       Impact factor: 3.616

10.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

View more
  33 in total

1.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Simultaneous mutations in CA and Vif of Maedi-Visna virus cause attenuated replication in macrophages and reduced infectivity in vivo.

Authors:  Bjarki Gudmundsson; Stefán Ragnar Jónsson; Oddur Olafsson; Gudrún Agnarsdóttir; Sigrídur Matthíasdóttir; Gudmundur Georgsson; Sigurbjorg Torsteinsdóttir; Vilhjálmur Svansson; Helga Bryndís Kristbjornsdóttir; Sigrídur Rut Franzdóttir; Olafur S Andrésson; Valgerdur Andrésdóttir
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Feline immunodeficiency virus Vif localizes to the nucleus.

Authors:  U Chatterji; C K Grant; J H Elder
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

Review 6.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

7.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.

Authors:  M Bouyac; M Courcoul; G Bertoia; Y Baudat; D Gabuzda; D Blanc; N Chazal; P Boulanger; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions.

Authors:  M Dettenhofer; X F Yu
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.